| Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ... New England journal of medicine 369 (2), 134-144, 2013 | 4249 | 2013 |
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial C Robert, A Ribas, JD Wolchok, FS Hodi, O Hamid, R Kefford, JS Weber, ... The Lancet 384 (9948), 1109-1117, 2014 | 2161 | 2014 |
| Phase I study of pembrolizumab (MK-3475; anti–PD-1 monoclonal antibody) in patients with advanced solid tumors A Patnaik, SP Kang, D Rasco, KP Papadopoulos, J Elassaiss-Schaap, ... Clinical cancer research 21 (19), 4286-4293, 2015 | 857 | 2015 |
| Diurnal modulation of pacemaker potentials and calcium current in the mammalian circadian clock CMA Pennartz, MTG de Jeu, NPA Bos, J Schaap, AMS Geurtsen Nature 416 (6878), 286-290, 2002 | 295 | 2002 |
| Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab RW Joseph, J Elassaiss-Schaap, R Kefford, WJ Hwu, JD Wolchok, ... Clinical Cancer Research 24 (20), 4960-4967, 2018 | 287 | 2018 |
| Heterogeneity of rhythmic suprachiasmatic nucleus neurons: Implications for circadian waveform and photoperiodic encoding J Schaap, H Albus, HT VanderLeest, PHC Eilers, L Détári, JH Meijer Proceedings of the National Academy of Sciences 100 (26), 15994-15999, 2003 | 255 | 2003 |
| Acute and 2-week exposure to prednisolone impair different aspects of β-cell function in healthy men DH van Raalte, V Nofrate, MC Bunck, T van Iersel, J Elassaiss Schaap, ... European Journal of Endocrinology 162 (4), 729-735, 2010 | 226 | 2010 |
| Model‐based characterization of the pharmacokinetics of pembrolizumab: a humanized anti–PD‐1 monoclonal antibody in advanced solid tumors M Ahamadi, T Freshwater, M Prohn, CH Li, DP De Alwis, R De Greef, ... CPT: pharmacometrics & systems pharmacology 6 (1), 49-57, 2017 | 174 | 2017 |
| Translational pharmacokinetic/pharmacodynamic modeling of tumor growth inhibition supports dose‐range selection of the anti–PD‐1 antibody pembrolizumab A Lindauer, CR Valiathan, K Mehta, V Sriram, R De Greef, ... CPT: pharmacometrics & systems pharmacology 6 (1), 11-20, 2017 | 135 | 2017 |
| Using model‐based “learn and confirm” to reveal the pharmacokinetics‐pharmacodynamics relationship of pembrolizumab in the KEYNOTE‐001 Trial J Elassaiss‐Schaap, S Rossenu, A Lindauer, SP Kang, R De Greef, ... CPT: pharmacometrics & systems pharmacology 6 (1), 21-28, 2017 | 112 | 2017 |
| Population pharmacokinetic/pharmacodynamic modeling of tumor size dynamics in pembrolizumab‐treated advanced melanoma MS Chatterjee, J Elassaiss‐Schaap, A Lindauer, DC Turner, A Sostelly, ... CPT: pharmacometrics & systems pharmacology 6 (1), 29-39, 2017 | 93 | 2017 |
| Neurons of the rat suprachiasmatic nucleus show a circadian rhythm in membrane properties that is lost during prolonged whole-cell recording J Schaap, NPA Bos, MTG de Jeu, AMS Geurtsen, JH Meijer, ... Brain research 815 (1), 154-166, 1999 | 88 | 1999 |
| Electrophysiology of the circadian pacemaker in mammals J Schaap, CMA Pennartz, JH Meijer Chronobiology international 20 (2), 171-188, 2003 | 70 | 2003 |
| Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. RW Joseph, J Elassaiss-Schaap, JD Wolchok, AM Joshua, A Ribas, ... Journal of Clinical Oncology 32 (15_suppl), 3015-3015, 2014 | 60 | 2014 |
| Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3. 0 simulations MAA Saleh, CF Loo, J Elassaiss-Schaap, ECM De Lange Journal of pharmacokinetics and pharmacodynamics 48 (5), 725-741, 2021 | 43 | 2021 |
| Pembrolizumab: role of modeling and simulation in bringing a novel immunotherapy to patients with melanoma R De Greef, J Elassaiss‐Schaap, M Chatterjee, DC Turner, M Ahamadi, ... CPT: Pharmacometrics & Systems Pharmacology 6 (1), 5-7, 2017 | 31 | 2017 |
| Multivariate pharmacokinetic/pharmacodynamic (PKPD) analysis with metabolomics shows multiple effects of remoxipride in rats WJ Van den Brink, J Elassaiss-Schaap, B Gonzalez-Amoros, AC Harms, ... European Journal of Pharmaceutical Sciences 109, 431-440, 2017 | 15 | 2017 |
| Assessment of pembrolizumab (MK-3475) dosing strategy based on population pharmacokinetics and exposure-response models T Freshwater, J Stone, R de Greef, A Kondic, DP De Alwis, K Mayawala, ... Journal of Pharmacokinetics and Pharmacodynamics 42, S15-S15, 2015 | 15 | 2015 |
| Variability as constant coefficient of variation: can we right two decades in error J Elassaiss-Schaap, SH Heisterkamp Population Approach Group in Europe (PAGE) meeting, 2009 | 14 | 2009 |
| Variability in the log domain and limitations to its approximation by the normal distribution J Elassaiss‐Schaap, K Duisters CPT: Pharmacometrics & Systems Pharmacology 9 (5), 245-257, 2020 | 13 | 2020 |
